Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
Chionh F, Gebski V, Al-Obaidi SJ, Mooi JK, Bruhn MA, Lee CK, Chüeh AC, Williams DS, Weickhardt AJ, Wilson K, Scott AM, Simes J, Hardingham JE, Price TJ, Mariadason JM, Tebbutt NC. Chionh F, et al. Among authors: scott am. Sci Rep. 2022 Jan 24;12(1):1238. doi: 10.1038/s41598-021-03952-y. Sci Rep. 2022. PMID: 35075138 Free PMC article. Clinical Trial.
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM. Chong G, et al. Among authors: scott am. Clin Cancer Res. 2005 Jul 1;11(13):4818-26. doi: 10.1158/1078-0432.CCR-04-2330. Clin Cancer Res. 2005. PMID: 16000579 Clinical Trial.
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ. Scott AM, et al. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. doi: 10.1073/pnas.0611693104. Epub 2007 Feb 28. Proc Natl Acad Sci U S A. 2007. PMID: 17360479 Free PMC article. Clinical Trial.
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ. Scott AM, et al. Clin Cancer Res. 2007 Jun 1;13(11):3286-92. doi: 10.1158/1078-0432.CCR-07-0284. Clin Cancer Res. 2007. PMID: 17545534 Clinical Trial.
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.
Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM. Herbertson RA, et al. Among authors: scott am. Clin Cancer Res. 2009 Nov 1;15(21):6709-15. doi: 10.1158/1078-0432.CCR-09-0536. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825951 Free PMC article. Clinical Trial.
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. Among authors: scott am. J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412142 Clinical Trial.
716 results